초록 ▼

An implantable delivery system includes a macrostructure formed of bioresorbable material selected from a group of alphahydroxy acids and defined to include an internal architecture of intercommunicating void spaces. A first cytotoxic agent in the preferred form of cisplatin is joined to the macrost

An implantable delivery system includes a macrostructure formed of bioresorbable material selected from a group of alphahydroxy acids and defined to include an internal architecture of intercommunicating void spaces. A first cytotoxic agent in the preferred form of cisplatin is joined to the macrostructure during formation. A microstructure in the preferred form of a blend of high molecular weight hyaluronic acid conjugated with a second cytotoxic agent in the preferred form of paclitaxel and of pure high molecular weight hyaluronic acid is invested in the void spaces. Thus, when implanted, the paclitaxel and cisplatin are released sequentially, each initially at high level concentrations followed by lower release. Radiotherapy can be begun after the release of the paclitaxel has been completed but while the cisplatin is being released.

대표청구항 ▼

1. A surgical method comprising: conjugating a high molecular weight hyaluronic acid with a cytotoxic agent to create a conjugation which is hydrophilic; providing a bioresorbable delivery vehicle for the conjugation; and implanting into tissue of a living being containing one or more cancers treata

1. A surgical method comprising: conjugating a high molecular weight hyaluronic acid with a cytotoxic agent to create a conjugation which is hydrophilic; providing a bioresorbable delivery vehicle for the conjugation; and implanting into tissue of a living being containing one or more cancers treatable by the cytotoxic agent, the bioresorbable delivery vehicle and the conjugation as a cargo for treating said tissue. 2. The surgical method of claim 1, further comprising combining high molecular weight hyaluronic acid blended with said conjugation. 3. The surgical method of claim 2, wherein said high molecular weight hyaluronic acid is blended with the conjugation by a mass ratio in the order of 1:1. 4. The surgical method of claim 2, further comprising combining another cytotoxic agent different from but complimentary to the cytotoxic agent, with the other cytotoxic agent being a passive cargo residing in the delivery vehicle for sequential delivery to the tissue after the cytotoxic agent of the conjugation. 5. The surgical method of claim 4, wherein the bioresorbable delivery vehicle has a gross size, shape, architecture and mechanical characteristics to dictate a final three-dimensional morphology of repair tissue for the tissue. 6. The surgical method of claim 5, wherein the bioresorbable delivery vehicle is formed of a bioresorbable material comprising at least one alphahydroxyl acid. 7. The surgical method of claim 6, wherein the bioresorbable delivery device is fabricated in the form of a porous sponge having randomly sized, randomly shaped and infinitely intercommunicating interstices. 8. The surgical method of claim 7, with the molecular weight of the high molecular weight hyaluronic acid being in the range of 40-60 kilodaltons. 9. The surgical method of claim 8, with the cytotoxic agent of the conjugation being paclitaxel. 10. The surgical method of claim 9, with the other cytotoxic agent being cisplatin. 11. The surgical method of claim 4, wherein the bioresorbable delivery vehicle is hydrophobic, with the cytotoxic agent being a cargo in the bioresorbable delivery vehicle for delivery of the cytotoxic agent during resorption of the bioresorbable delivery vehicle, with the bioresorbable delivery vehicle including void spaces; and wherein combining the other cytotoxic agent comprises providing another bioresorbable delivery vehicle which is hydrophilic, with the other cytotoxic agent being a cargo in the other bioresorbable delivery vehicle for delivery of the other cytotoxic agent during resorption of the other bioresorbable delivery vehicle, with the other bioresorbable delivery vehicle and the other cytotoxic agent located in the void spaces of the bioresorbable delivery vehicle. 12. The surgical method of claim 11, further comprising chemically binding the other cytotoxic agent to the other bioresorbable delivery vehicle. 13. The surgical method of claim 12, with the other bioresorbable delivery vehicle being hyaluroric acid conjugated to the other cytotoxic agent. 14. The surgical method of claim 13, with the hyaluronic acid having a high molecular weight. 15. The surgical method of claim 14, with the high molecular weight of the hyaluronic acid being in the range of 40-60 kilodaltons. 16. The surgical method of claim 15, with the other cytotoxic agent being paclitaxel. 17. The surgical method of claim 16, with the cytotoxic agent being cisplatin. 18. The surgical method of claim 17, with the void spaces of the bioresorbable delivery vehicle defined by an internal architecture of partially enclosed, randomly sized, shaped and positioned intercommunicating instersties dictating a final three-dimensional morphology of repair tissue. 19. The surgical method of claim 11, with the cytotoxic agent adapted to damage a cell's ability to accurately replicate, and with the other cytotoxic agent adapted to paralyze a cell's cytoskeleton. 20. The surgical method of claim 1, wherein implanting comprises implanting into tissue containing one or more cancers selected from the group consisting of breast cancer, prostrate cancer and colon cancer.